Synopsis of new antiangiogenetic factors, mutation compensation agents, and monoclonal antibodies in target therapies of breast cancer

J BUON. 2010 Oct-Dec;15(4):639-46.

Abstract

Breast cancer is the most common type of cancer among females and the 5th most common cause of cancer death. About 5-10% of breast cancers occur due to gene mutations inherited from mother or father. The molecular basis of breast cancer has been extensively investigated, making gene therapy a potential new therapeutic alternative. Mutation compensation, molecular chemotherapy, proapoptotic gene therapy, antiangiogenic gene therapy, genetic immunopotentiation and genetic modulation of resistance/sensitivity are the main gene therapies used. The combination of gene therapy with chemotherapy or radiation is being investigated in ongoing trials. The purpose of this review was to make a synopsis of the currently existing target therapies in breast cancer.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / immunology
  • Breast Neoplasms / therapy*
  • Clinical Trials as Topic
  • Female
  • Genetic Therapy*
  • Humans
  • Immunotherapy*
  • Mutation / drug effects*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents